Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jamie M. Pitlick
Mirabegron: A Beta-3 Agonist for Overactive Bladder
The Consultant Pharmacist
Related publications
Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder
Research and Reports in Urology
Urology
Persistence and Adherence With Mirabegron, a New Beta-3 Receptor Agonist, Versus Antimuscarinics in Overactive Bladder: Early Experience in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
New Developments in the Management of Overactive Bladder: Focus on Mirabegron and onabotulinumtoxinA
Therapeutics and Clinical Risk Management
The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study
BMC Urology
Medicine
Reproductive Medicine
Urology
Effectiveness of an Intervention to Optimise the Use of Mirabegron for Overactive Bladder: A Quasi-Experimental Study in Primary Care
British Journal of General Practice
Medicine
Family Practice
Efficacy and Tolerability of Mirabegron in Female Patients With Overactive Bladder Symptoms After Surgical Treatment for Stress Urinary Incontinence
International braz j urol : official journal of the Brazilian Society of Urology
Medicine
Urology
Refractory Overactive Bladder: A Common Problem?
International Urogynecology Journal
Gynecology
Urology
Obstetrics
Factors Associated With Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
Advances in Therapy
Medicine
Pharmacology
